Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 6/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 6/20 | 0.36 |
| ▸ | FLT1 | P17948 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640464 | 0.94 | EGFR (0.41) | EGFRAURKARPS6KB1AURKBKDR | |
| SCHEMBL19650876 | 0.91 | AURKA (0.37) | EGFRAURKARPS6KB1AURKBLMNA | |
| SCHEMBL19650879 | 0.88 | VNN1 (0.38) | EGFRAURKARPS6KB1AURKBLMNA | |
| SCHEMBL19650857 | 0.88 | AURKA (0.33) | EGFRAURKARPS6KB1AURKBLMNA | |
| SCHEMBL19650873 | 0.87 | AURKA (0.35) | EGFRAURKARPS6KB1AURKBLMNA | |
| SCHEMBL19650897 | 0.87 | AURKA (0.33) | EGFRAURKARPS6KB1AURKBLMNA | |
| SCHEMBL19650844 | 0.87 | PDE10A (0.38) | EGFRAURKARPS6KB1AURKBLMNA | |
| SCHEMBL19650875 | 0.87 | AURKA (0.36) | EGFRAURKARPS6KB1AURKBKDR | |
| SCHEMBL19650845 | 0.86 | RPS6KB1 (0.42) | AURKARPS6KB1AURKBRORC | |
| SCHEMBL19640415 | 0.86 | AURKA (0.43) | EGFRAURKARPS6KB1AURKBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342074-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342074-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | EGFR 1169/4885AURKA 1448/4885RPS6KB1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.